ストックスクリーナーアプリを入手
24.70
2.56%
-0.65
アフターアワーズ：
24.78
0.08
+0.32%
前日終値:
$25.35
開ける：
$25.44
24時間の取引高:
8.71M
Relative Volume:
0.86
時価総額：
$9.61B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-2.8293
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
-8.01%
1か月 パフォーマンス:
-2.49%
6か月 パフォーマンス:
-11.21%
1年 パフォーマンス:
-55.27%
1日の値動き範囲:
$24.41
$25.55
1週間の範囲:
$24.41
$27.37
52週間の値動き範囲:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.70 | 9.90B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
US health agency fires official who opposed mRNA Covid shots - MarketScreener
New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle
AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat
Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock trades before earningsWatch List & Community Verified Swing Trade Signals - newser.com
Will Moderna Inc. stock see insider buyingJuly 2025 Breakouts & Verified Momentum Watchlists - Fundação Cultural do Pará
Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360
What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Moderna Inc. stockDollar Strength & Growth Oriented Trade Recommendations - newser.com
Using economic indicators to assess Moderna Inc. potentialTrade Ideas & Real-Time Price Movement Reports - newser.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
D.A. Davidson & CO. Purchases 62,778 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is favored by top institutionsJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Is Moderna Inc. stock in correction or buying zonePortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Analysts Set Expectations for Moderna FY2026 Earnings - MarketBeat
FY2026 EPS Estimates for Moderna Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for Moderna Q3 Earnings - MarketBeat
Moderna (NASDAQ:MRNA) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Is it too late to sell Moderna Inc.IPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Moderna scraps mRNA vaccine in congenital CMV on trial failure - Medical Dialogues
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Daily News Journal
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
How moving averages guide Moderna Inc. trading2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Moderna to Host Investor Event – Analyst Day - Shelby Star
Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Bluffton Today
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Pueblo Chieftain
Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap Down Following Analyst Downgrade - MarketBeat
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Daily Jeffersonian
UBS Maintains Moderna (MRNA) Buy Recommendation - Nasdaq
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Holland Sentinel
How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo Finance
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Asheville Citizen Times
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Ra - GuruFocus
Moderna’s cytomegalovirus vaccine fails a phase III - BioWorld MedTech
Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely - Citeline News & Insights
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
1.60%
大文字化:
|
ボリューム (24 時間):